News | Treatment Planning | August 23, 2019

Heidelberg University Hospital Treats First Patient Using Carbon Ion Therapy With RayStation

German hospital plans to use RayStation for all proton and carbon ion therapy treatment planning, including helium ion therapy beginning in 2020

Heidelberg University Hospital Treats First Patient Using Carbon Ion Therapy With RayStation

August 23, 2019 — Heidelberg University Hospital, Germany, has started using the RayStation treatment planning system for carbon ion therapy treatments. The center is now using RayStation for both particle therapy and photon therapy.

In April 2018, RayStation was selected as the treatment planning system for Heidelberg Ion Beam Therapy Center (HIT), which is the leading German facility for proton and carbon ion therapy and part of the Heidelberg University Hospital. An additional RayStation order for photon therapy was placed later that year, and RaySearch and Heidelberg University Hospital also entered into a long-term collaborative agreement regarding the clinical introduction of the RayCare oncology information system.

HIT has long expertise in advanced radiation therapy techniques and has been performing proton therapy and carbon ion therapy for the past 10 years. The center is now replacing its existing treatment planning system for protons and carbon ions and aims to use RayStation exclusively. Heidelberg University Hospital also treats patients using TomoTherapy, which is the focus of another cooperation between HIT and RaySearch. In addition, the center aims to begin treating patients using helium ion therapy by 2020. RayStation enables treatment planning for all of these modalities with a single software platform.

The HIT facility is an in-house medical product integrating a particle accelerator, a rotating ion gantry and an Iontris delivery system from Siemens Healthcare. The setup includes three treatment rooms, two horizontal treatment rooms,  and one gantry for both carbon ion and proton therapy. The gantry is the world’s first for carbon ion therapy. The facility has the capacity to treat up to 1,000 patients per year using particle therapy.

Jürgen Debus, professor and chairman, radiation oncology at Heidelberg University Hospital, said, “Carbon ion treatment planning in RayStation offers us unique options to optimize our treatment plans along with proton and photon precision radiotherapy.”

For more information: www.raysearchlabs.com

Related Content

Nuclear imaging equipment growth in 2020
News | Nuclear Imaging | February 14, 2020
February 14, 2020 — The nuclear imaging equipment
Varian announced it has received FDA 510(k) clearance for its Ethos therapy, an Adaptive Intelligence solution. Ethos therapy is an artificial intelligence (AI)-driven holistic solution that provides an opportunity to transform cancer care.
News | Image Guided Radiation Therapy (IGRT) | February 11, 2020
February 11, 2020 — Varian announced it has received FDA 510(k) c
The radiation therapy market is projected to grow in through 2026

Image courtesy of Accuray

News | Proton Therapy | February 10, 2020
February 10, 2020 — Amid technological advancement, and notable research and development activities, the global ...
SIR President Laura Findeiss, M.D., FSIR

SIR President Laura Findeiss, M.D., FSIR

News | Interventional Radiology | February 09, 2020
February 9, 2020 — For some patients, kidney cancer can be effectively treated without surgery, according to the...
Accuray TomoTherapy total body irradiation
News | Radiation Therapy | February 07, 2020
February 7, 2020 — Accuray Incorporated announced that two new studies demonstrate the benefits of the ...
Purdue University-discovered fluorescent markers to target and illuminate cancer during surgery, has announced the results of a multi-institutional Phase 2 clinical trial in which outcomes were improved for 26 percent of patients undergoing pulmonary resection for non-small-cell lung cancer (NSCLC)

A Purdue discovery being developed by On Target Laboratories Inc., illuminates lung cancer cells on a patient during surgery. The “fluorescent markers” help medical professionals identify and remove cancer cells during surgery and is shown to improve outcomes. The technology is beginning Phase 3 clinical trials. (Photo provided by On Target)

News | Molecular Imaging | February 06, 2020
February 6, 2020 — ...
The luminescent oxygen probe PtG4 is injected during the week of radiation treatment and localizes between the cells of the tumor as illustrated by microscopy

An oxygen map image recovered from a mouse undergoing radiation therapy. The luminescent oxygen probe PtG4 is injected during the week of radiation treatment and localizes between the cells of the tumor as illustrated by microscopy (red). Image courtesy of Brian Pogue, PhD

News | Radiation Therapy | February 03, 2020
February 3, 2020 — Oxygen in cancer tumors is known to be a major factor that helps radiation therapy be successful.
News | Clinical Trials | February 03, 2020
February 3, 2020 — Melding the genetic and cellular analysis of tumors with how they appear in medical images could g
Elekta Unity MR Linac system
News | Radiation Oncology | January 30, 2020
January 30, 2020 — Elekta announced that it signed a contract wit